Replies to post #209597 on Cytodyn Inc (CYDY)

[misiu143]

" The attacks are relentless and why is that if the company is done for "

Obviously company is not done ..

With results like leronlimab how is that possible..

--In HIV combo , our pivotal trial for MDR 2 and 3 patients ,
finished with 81% efficacy and not one severe side effect reported , compare to other approved companies below ,
....Maraviroc with 45% efficacy , and severe side effects , and ..
....Ibalizumab with 43% efficacy , and some severe side effects..

--In cancer , look that we already better in TNBC then Trodelvy , and what a difference in side effects.
In compassionate studies and INDs we have patients with no other available treatment , doing well with leronlimab , these are some with pancreatic cancer , urinary bladder , colon , different breast cancers , and others ..we looking for a partners, I will expect it may happen this year..

--NASH , we all waiting for Topline results in both 350 and 700 mg , probably they are very good , since it was accepted for International Conference June 25 , so soon we will know..
If as good as some of us think , partner should be close by..

--Covid we had great results with critical for now , showing that 2 doses are not enough , but when leronlimab is still in the system we see 82% mortality benefit ABOVE all other drugs..
I predict that with proper dose it will be also great in severe..

--In Long Covid phase 2 , we saw great results and important discovery..
During last CC Dr Kelly said they looking for a partner for phase 3 , this too should be this year I will think..

Preclinical studies are done and expect good results..

--University Hospital in London , England for Alz.
--University Center in Boston with CAR-T treatment.
--One of the University Center in NYC with Glioblastoma
--Ongoing study in MD Anderson with check point inhibitors.

Yes , a lot of things going on in this company.. Very imprtant things ..

All imo.

GLTA longs .